-
Something wrong with this record ?
Differential effect of baclofen on cortical and spinal inhibitory circuits
I. Stetkarova, M. Kofler,
Language English Country Netherlands
Document type Clinical Trial, Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
Grant support
NT12282
MZ0
CEP Register
- MeSH
- GABA-B Receptor Agonists administration & dosage pharmacology MeSH
- Baclofen administration & dosage pharmacology MeSH
- Time Factors MeSH
- Adult MeSH
- H-Reflex drug effects physiology MeSH
- Muscle, Skeletal innervation MeSH
- Middle Aged MeSH
- Humans MeSH
- Spinal Nerves drug effects physiopathology MeSH
- Cerebral Cortex drug effects physiopathology MeSH
- Spinal Injuries complications MeSH
- Reaction Time drug effects physiology MeSH
- Reflex drug effects physiology MeSH
- Multiple Sclerosis complications MeSH
- Injections, Spinal MeSH
- Muscle Spasticity etiology physiopathology MeSH
- Check Tag
- Adult MeSH
- Middle Aged MeSH
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
OBJECTIVE: The cutaneous silent period (SP) is a spinal inhibitory reflex, which suppresses activity in spinal motor nuclei. Transcranial magnetic stimulation (TMS) elicits a cortical SP, which represents GABA(B) receptor-mediated inhibition of cortical excitability. Baclofen as a strong GABA(B) agonist effectively reduces muscle hypertonia, however, it is not known whether intrathecal baclofen (ITB) may modulate spinal inhibitory circuits. METHODS: We evaluated clinical and neurophysiological effects of ITB in ten patients with severe spasticity due to spinal cord injury (n = 9) and chronic progressive multiple sclerosis (n = 1). Neurophysiological assessment included H reflex and cutaneous and cortical SPs, before and 15, 30, 60, 90, 120, and 180 min after ITB bolus administration. RESULTS: ITB suppressed soleus H reflex as early as 15 min after lumbar bolus injection; MAS scores declined after 1 h. Cortical SP end latency and duration increased progressively with a significant maximum 3h following ITB bolus, whereas cutaneous SP latency and duration did not change significantly. CONCLUSION: The present findings suggest that baclofen does not affect the cutaneous SP, but prolongs the cortical SP. SIGNIFICANCE: The spinal inhibitory circuitry of the cutaneous SP is not modulated by GABA(B) receptor-mediated activity, in contrast to the cortical inhibitory circuitry of the cortical SP, which is subject to powerful GABA(B) control.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13024358
- 003
- CZ-PrNML
- 005
- 20181018105126.0
- 007
- ta
- 008
- 130703s2013 ne f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.clinph.2012.07.005 $2 doi
- 035 __
- $a (PubMed)22877625
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a ne
- 100 1_
- $a Štětkářová, Ivana, $u Department of Neurology, 3rd Medical Faculty, Charles University, Prague, Czech Republic. ivana.stetkarova@fnkv.cz $d 1963- $7 xx0030376
- 245 10
- $a Differential effect of baclofen on cortical and spinal inhibitory circuits / $c I. Stetkarova, M. Kofler,
- 520 9_
- $a OBJECTIVE: The cutaneous silent period (SP) is a spinal inhibitory reflex, which suppresses activity in spinal motor nuclei. Transcranial magnetic stimulation (TMS) elicits a cortical SP, which represents GABA(B) receptor-mediated inhibition of cortical excitability. Baclofen as a strong GABA(B) agonist effectively reduces muscle hypertonia, however, it is not known whether intrathecal baclofen (ITB) may modulate spinal inhibitory circuits. METHODS: We evaluated clinical and neurophysiological effects of ITB in ten patients with severe spasticity due to spinal cord injury (n = 9) and chronic progressive multiple sclerosis (n = 1). Neurophysiological assessment included H reflex and cutaneous and cortical SPs, before and 15, 30, 60, 90, 120, and 180 min after ITB bolus administration. RESULTS: ITB suppressed soleus H reflex as early as 15 min after lumbar bolus injection; MAS scores declined after 1 h. Cortical SP end latency and duration increased progressively with a significant maximum 3h following ITB bolus, whereas cutaneous SP latency and duration did not change significantly. CONCLUSION: The present findings suggest that baclofen does not affect the cutaneous SP, but prolongs the cortical SP. SIGNIFICANCE: The spinal inhibitory circuitry of the cutaneous SP is not modulated by GABA(B) receptor-mediated activity, in contrast to the cortical inhibitory circuitry of the cortical SP, which is subject to powerful GABA(B) control.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a baklofen $x aplikace a dávkování $x farmakologie $7 D001418
- 650 _2
- $a mozková kůra $x účinky léků $x patofyziologie $7 D002540
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a agonisté receptorů GABA-B $x aplikace a dávkování $x farmakologie $7 D058786
- 650 _2
- $a H-reflex $x účinky léků $x fyziologie $7 D006181
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a spinální injekce $7 D007278
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a roztroušená skleróza $x komplikace $7 D009103
- 650 _2
- $a svalová spasticita $x etiologie $x patofyziologie $7 D009128
- 650 _2
- $a kosterní svaly $x inervace $7 D018482
- 650 _2
- $a reakční čas $x účinky léků $x fyziologie $7 D011930
- 650 _2
- $a reflex $x účinky léků $x fyziologie $7 D012018
- 650 _2
- $a poranění páteře $x komplikace $7 D013124
- 650 _2
- $a míšní nervy $x účinky léků $x patofyziologie $7 D013127
- 650 _2
- $a časové faktory $7 D013997
- 655 _2
- $a klinické zkoušky $7 D016430
- 655 _2
- $a srovnávací studie $7 D003160
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kofler, Markus $u -
- 773 0_
- $w MED00005214 $t Clinical neurophysiology official journal of the International Federation of Clinical Neurophysiology $x 1872-8952 $g Roč. 124, č. 2 (2013), s. 339-345
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/22877625 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20130703 $b ABA008
- 991 __
- $a 20181018105626 $b ABA008
- 999 __
- $a ok $b bmc $g 988038 $s 822738
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 124 $c 2 $d 339-345 $i 1872-8952 $m Clinical neurophysiology $n Clin Neurophysiol $x MED00005214
- GRA __
- $a NT12282 $p MZ0
- LZP __
- $a Pubmed-20130703